Which supplements actually have evidence in ulcerative colitis? What a 2026 network meta-analysis found — and what it didn't

If you live with ulcerative colitis (UC), the supplement question comes up early. A friend swears by curcumin. A relative read about probiotics. Someone in a group says vitamin A helped. The shelves are full and the answers feel scattered.

A 2026 paper in Frontiers in Medicine tried to bring some order to that shelf. It is a network meta-analysis — a method that pools many small trials and lets researchers compare different treatments against each other, even when they were never tested head-to-head — and it looked specifically at dietary supplements used alongside, or instead of, standard UC care. We want to read it carefully, because "the network meta-analysis says…" is the kind of sentence that can run ahead of what the underlying evidence actually supports [3].

What the review actually did

UC is a long-term inflammatory condition of the colon and rectum. Symptoms include bloody diarrhoea, urgency, and fatigue, and the aim of treatment is to reduce inflammation and keep the disease in remission — something authority guidance frames as a clinician-led process with medicines, not as a do-it-yourself project [1].

The 2026 review searched PubMed, Cochrane Library, Embase and Web of Science up to October 2025 for randomized controlled trials that tested dietary supplements in adults with UC. It ended up pooling 24 trials, covering 14 different supplements in 1,491 people, and comparing each one against conventional medical treatment or placebo on four kinds of outcome: clinical activity, Mayo score (a structured disease-activity measure), quality of life on the IBDQ questionnaire, and inflammatory markers like CRP [2].

That is — for a topic this loud — actually quite a small evidence pool: 14 supplements split across 24 trials means many of the comparisons rest on one or two studies each.

What it found

In broad strokes, compared with conventional treatment or placebo, the review reports [3]:

• Probiotics and selenium were associated with reduced clinical activity index.
• Flaxseed extract and vitamin A were associated with reduced Mayo score.
• Probiotics, flaxseed extract, resveratrol, curcumin, and butyrate were associated with higher IBDQ quality-of-life scores.
• Synbiotics, flaxseed extract, and Achillea wilhelmsii (a herbal preparation) were associated with reduced CRP.

Flaxseed extract is the name that shows up across multiple outcomes in this particular analysis. That is the part of the abstract that travels well. It is also the part most easily over-read.

What it didn't say

The authors' own conclusion is, in our reading, the most important sentence in the whole paper [4]:

"Due to the limitations of the number and quality of included studies, the above conclusions still need to be validated by more high-quality, large-sample RCTs."

That matters for two reasons. The first is statistical: when each supplement is represented by a small handful of small trials, the "effect size" you can read off a forest plot is genuinely uncertain. Network meta-analysis is a useful technique here, but it does not generate new evidence — it can only re-arrange what already exists.

The second reason is clinical. Even the supplements with the cleanest signal in this review are described as adjuvant — used alongside UC treatment, not instead of it — and authority guidance is explicit that diet and supplement decisions for inflammatory bowel disease should happen with a clinician, because nutritional needs and medication interactions are not one-size-fits-all [5].

What this means for someone living with UC

A network meta-analysis like this is best treated as a map of where the evidence is starting to gather, not as a shopping list. Some candidates — probiotics, butyrate, curcumin, flaxseed extract — have enough signal in this snapshot to make them reasonable things to ask about at a clinic appointment. None of them are positioned in this review as ready to replace standard care.

A few practical points stay constant:

• A supplement that is "natural" can still interact with UC medication or affect lab values; this is one of the reasons clinicians want to know what you are taking.
• Quality of life is not a small outcome. Some of the signals here (probiotics, flaxseed, curcumin, butyrate) showed up on the IBDQ — that captures real-life things like sleep, social life, and energy. It is worth taking seriously even if disease-activity findings stay modest.
• Larger, better-designed trials are the missing piece. Until those arrive, individual results in network meta-analyses like this are best read as "interesting, not settled".

If you are wondering whether a supplement is worth adding — for yourself or for someone you care for — that's a conversation for your gastroenterologist or IBD nurse, who can weigh it against your current regimen and the specifics of your disease.